Pachydrusen-associated AMD may progress slower than typical AMD. Age and macular pigment changes increase the risk of complications. Current AMD risk models may not apply to eyes with pachydrusen. AMD ...

As many as 15 million people in the United States have some form of age-related macular degeneration, a leading cause of vision loss among people 50 and older. Nine out of 10 of them have the dry form ...

Age-related macular degeneration (AMD) is a major cause of blindness, especially in older adults. A key feature of early AMD is the formation of drusen, clumps of debris made of lipids and proteins ...

Age-related macular degeneration, also called AMD, is the deterioration of the center of the retina called the macula. The macula is the part of the retina which is responsible for our central vision ...

OCT image of SDDs (marked by yellow arrows) in the retina of a patient with prior MI. Photo Credit: Mount Sinai Health System. Among patients with age-related macular degeneration (AMD), those whose ...

A review of data on 2 mitochondrial membrane stabilizers—risuteganib and elamipretide—has highlighted the potential to not just slow disease progression but actually reverse vision loss in patients ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. More specifically, this ...

Both environmental factors (smoking, poor nutrition, etc.) and genetic factors contribute to the progression of AMD. In patients with bilateral AMD, only 54% were found to have symmetric disease, ...

Age-related macular degeneration (AMD) has a worldwide incidence of between 30 and 50 million people and is expected to affect up to 288 million people by the year 2040. Globally, AMD constitutes 6% ...

Conditions that resemble age-related macular degeneration (AMD) can differ considerably from AMD regarding prognosis, inheritance, monitoring and therapy. Differential diagnoses of AMD include other ...